

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT WITH JINBO BIO-PHARMACEUTICAL

This is a voluntary announcement made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”). The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on December 28, 2023, the Company entered into a non-legally binding strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. (山西錦波生物醫藥股份有限公司) (“**Jinbo Bio-Pharmaceutical**”).

Jinbo Bio-Pharmaceutical, listed on the Beijing Stock Exchange (stock code: 832982), is mainly engaged in the research, development, production, and sales of various medical devices and functional skincare products with recombinant humanized collagen protein products and anti-HPV bioproducts as its core products. It is the world’s first manufacturer of recombinant humanized collagen protein biopolymer materials and has set up the standard for recombinant humanized collagen protein (YY/T1888–2023 “Recombinant Humanized Collagen Protein”). Recombinant humanized collagen protein, as an original innovative biomaterial, is conducive to the development of new products that meet various application scenarios. The end products of Jinbo Bio-Pharmaceutical are mainly used in gynecology, dermatology, surgery, ophthalmology and otolaryngology, dentistry, proctology, skincare, and other fields with high market potential.

Pursuant to the Strategic Cooperation Agreement, the Group will be the exclusive general distributor of the sale of selective products of Jinbo Bio-Pharmaceutical in the offline pharmacy channel. During the term of cooperation, the parties will cooperate in the marketing and promotion, and sales of Jinbo Bio-Pharmaceutical's healthcare products by leveraging the Group's offline pharmacy network. The Group will also provide Jinbo Bio-Pharmaceutical with customized software services by leveraging its technology know-how. Via business cooperation, the parties hope to expand market width and enhance promotion efficiency for Jinbo Bio-Pharmaceutical through digitization, and to provide high-quality healthcare products for pharmacies within the Group's coverage.

The Board considers that the Strategic Cooperation Agreement provides a valuable opportunity to the parties to leverage their respective resources and expertise and create mutual benefits and synergy to each other. Therefore, the Board is of the view that entering into the Strategic Cooperation Agreement is in the interest of the Company and its shareholders as a whole.

To the best of the knowledge, information and belief of the Board having made all reasonable enquires, Jinbo Bio-Pharmaceutical is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). Further announcement(s) in relation to the possible cooperation will be made by the Company as and when appropriate in compliance with the Listing Rules. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, December 28, 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*